Can PARP inhibitors achieve therapeutic CNS exposure without causing peripheral toxicity in chronic dosing?

drug-development open composite 63%
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
63%
Novelty
70%
Mechanistic
—
Druggability
—
Priority
78%
Importance
78%
Tractability
85%
Market price
50%

Description

The expert identified that existing PARP inhibitors are optimized for cancer with poor brain penetration, while the chronic low-dose regimen needed for neurodegeneration remains untested. This pharmacokinetic gap is critical for translating the NAD+ depletion hypothesis to therapy.

Source: Debate session sess_SDA-2026-04-16-gap-20260416-133111 (Analysis: SDA-2026-04-16-gap-20260416-133111)